biote Corp.

NasdaqGM:BTMD Stock Report

Market Cap: US$124.6m

biote Future Growth

Future criteria checks 0/6

biote's earnings are forecast to decline at 52.2% per annum while its annual revenue is expected to grow at 7.7% per year. EPS is expected to decline by 62% per annum.

Key information

-52.2%

Earnings growth rate

-62.02%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate7.7%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Nov 2025

Recent future growth updates

Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates

biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Restructuring At Biote Will Drive Greater Growth And Profitability

Sep 10

Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates

Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet

Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet

biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings

May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings

biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward

Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward

Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues

Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
User avatar

Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value

Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.

biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside

Sep 27

Biote partners with IMAC Holdings

Sep 07

Earnings and Revenue Growth Forecasts

NasdaqGM:BTMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027213922202
12/31/20261971425285
12/31/20251922732345
9/30/2025196293440N/A
6/30/2025199313541N/A
3/31/2025199213744N/A
12/31/202419733845N/A
9/30/202419373340N/A
6/30/202418741924N/A
3/31/202418761821N/A
12/31/202318532427N/A
9/30/2023184-32426N/A
6/30/2023181-103032N/A
3/31/2023173-8-5-3N/A
12/31/2022165-1-11-9N/A
9/30/20221583-8-5N/A
6/30/202215211-9-5N/A
3/31/2022145242933N/A
12/31/2021139333034N/A
9/30/2021133372831N/A
12/31/2020117292526N/A
12/31/2019110212425N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BTMD's earnings are forecast to decline over the next 3 years (-52.2% per year).

Earnings vs Market: BTMD's earnings are forecast to decline over the next 3 years (-52.2% per year).

High Growth Earnings: BTMD's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BTMD's revenue (7.7% per year) is forecast to grow slower than the US market (10.7% per year).

High Growth Revenue: BTMD's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BTMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 05:08
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

biote Corp. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey Van SinderenB. Riley Securities, Inc.
Kaumil GajrawalaJefferies LLC
George KellyRoth Capital Partners